{"nctId":"NCT00200343","briefTitle":"Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis C","startDateStruct":{"date":"2002-07"},"conditions":["Chronic Hepatitis C"],"count":596,"armGroups":[{"label":"Ursodeoxycholic acid 150mg / day","type":"EXPERIMENTAL","interventionNames":["Drug: Ursodeoxycholic acid 150mg / day"]},{"label":"Ursodeoxycholic acid 600mg / day","type":"EXPERIMENTAL","interventionNames":["Drug: Ursodeoxycholic acid 600mg / day"]},{"label":"Ursodeoxycholic acid 900mg / day","type":"EXPERIMENTAL","interventionNames":["Drug: Ursodeoxycholic acid 900mg / day"]}],"interventions":[{"name":"Ursodeoxycholic acid 150mg / day","otherNames":[]},{"name":"Ursodeoxycholic acid 600mg / day","otherNames":[]},{"name":"Ursodeoxycholic acid 900mg / day","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Subject must have a clinical diagnosis to apply the conservative medication for chronic hepatitis C.\n2. Serum alanine aminotransferase levels measured at 4-week before the initiation of treatment must be over 61 IU/mL.\n3. Subject's age must be 20 years or older.\n\nExclusion Criteria:\n\n1. Subject who received a treatment of antiviral agents (interferon) within 20 weeks before the start of 8-week observation period\n2. Subject who received a treatment of corticosteroids, immunosuppressive drugs, glycyrrhizic acid, cholestyramine or other drugs which could interfere with hepatic function during 8-week observation period.\n3. Subject with decompensated cirrhosis\n4. Subject infecting with other hepatic virus\n5. Subject receiving a treatment for autoimmune disease, alcohol or drug-induced hepatic disorder, neoplasia, hepato-cholangiolar disease, fulminant hepatitis or peptic ulcer\n6. Subject who require hospitalization for complications of the heart, kidney or pancreas\n7. Pregnancy\n8. Alcoholics\n9. Alcohol intake more than 27 ml/day\n10. Subject who involved in other clinical trial within 4 weeks before the start of observation period\n11. Subject with a history of sensitivity to ursodeoxycholic acid or bile acid-products","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Alanine Aminotransferase at Baseline","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"109.2","spread":"49.7"},{"groupId":"OG001","value":"106.3","spread":"59.4"},{"groupId":"OG002","value":"110.6","spread":"57.3"}]}]}]},{"type":"SECONDARY","title":"Aspartate Aminotransferase at Baseline","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.0","spread":"39.1"},{"groupId":"OG001","value":"82.4","spread":"41.8"},{"groupId":"OG002","value":"85.2","spread":"45.0"}]}]}]},{"type":"SECONDARY","title":"Percentage Change of Aspartate Aminotransferase From Baseline at Week 24","description":"Percentage change=\\[(measured value at Week 24 - measured value at baseline)/measured value at baseline\\]\\*100","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.6","spread":null},{"groupId":"OG001","value":"-25.0","spread":null},{"groupId":"OG002","value":"-29.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Gamma-glutamyl Transpeptidase at Baseline","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.5","spread":"73.0"},{"groupId":"OG001","value":"82.4","spread":"62.2"},{"groupId":"OG002","value":"85.9","spread":"66.3"}]}]}]},{"type":"PRIMARY","title":"Percentage Change of Alanine Aminotransferase From Baseline at Week 24","description":"Percentage change=\\[(measured value at Week 24 - measured value at baseline)/measured value at baseline\\]\\*100","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.3","spread":null},{"groupId":"OG001","value":"-29.2","spread":null},{"groupId":"OG002","value":"-36.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change of Gamma-glutamyl Transpeptidase From Baseline at Week 24","description":"Percentage change=\\[(measured value at Week 24 - measured value at baseline)/measured value at baseline\\]\\*100","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.4","spread":null},{"groupId":"OG001","value":"-41.0","spread":null},{"groupId":"OG002","value":"-50.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":199},"commonTop":["Nasopharyngitis","Diarrhoea NOS","Headache","Back pain","Abdominal pain upper"]}}}